Efficacy and tolerability of switching therapy to vortioxetine versus other antidepressants in patients with major depressive disorder

References

• Fournier JC, Keener MT, Almeida J, et al. Amygdala and whole-brain activity to emotional faces distinguishes major depressive disorder and bipolar disorder. Bipolar Disord 2013;15:741-52
   PubMed Web of Science ®Google Scholar
• Daly EJ, Trivedi MH, Wisniewski SR, et al. Health-related quality of life in depression: a STAR*D report. Ann Clin Psychiatry 2010;22:43-55
   PubMed Web of Science ®Google Scholar
• World Health Organization. Fact sheet N°369. 2012
   Google Scholar
• Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006;3:e442 Available at: http://www.who.int/mediacentre/factsheets/fs369/en/ [Last accessed August 2015]
   PubMed Web of Science ®Google Scholar
• Ferrari AJ, Charlson FJ, Norman RE, et al. Burden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study 2010. PLoS Med 2013;10:e1001547
   PubMed Web of Science ®Google Scholar
• Gonda X, Fountoulakis KN, Kaprinis G, Rihmer Z. Prediction and prevention of suicide in patients with unipolar depression and anxiety. Ann Gen Psychiatry 2007;6:23
   PubMedGoogle Scholar
• Seguin M, Lesage A, Chawky N, et al. Suicide cases in New Brunswick from April 2002 to May 2003: the importance of better recognizing substance and mood disorder comorbidity. Can J Psychiatry 2006;51:581-6
   PubMed Web of Science ®Google Scholar
• Agency for Healthcare Research and Quality. Comparative Effectiveness Review Number 62: Treatment for Depression after Unsatisfactory Response to SSRIs. 2012
   Google Scholar
• Santaguida P, MacQueen G, Keshavarz H, Levine M, Beyene J, Raina P. Treatment for Depression After Unsatisfactory Response to SSRIs. Comparative Effectiveness Review No. 62. (Prepared by McMaster University Evidence-based Practice Center under Contract No. HHSA 290 2007 10060 I.) AHRQ Publication No.12-EHC050-EF. Rockville, MD: Agency for Healthcare Research and Quality; April 2012. http://www.ahrq.gov/clinic/epcix.htm.
   Google Scholar
• Qaseem A, Snow V, Denberg TD, et al. Using second-generation antidepressants to treat depressive disorders: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2008;149:725-33
   PubMed Web of Science ®Google Scholar
• Lam RW, Kennedy SH, Grigoriadis S, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. J Affect Disord 2009;117(Suppl 1):S26-43
   PubMed Web of Science ®Google Scholar
• Bauer M, Pfennig A, Severus E, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. World J Biol Psychiatry 2013;14:334-85
   PubMed Web of Science ®Google Scholar
• Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006;163:1905-17
   PubMed Web of Science ®Google Scholar
• Carvalho AF, Cavalcante JL, Castelo MS, Lima MC. Augmentation strategies for treatment-resistant depression: a literature review. J Clin Pharm Ther 2007;32:415-28
   PubMed Web of Science ®Google Scholar
• NICE. The Treatment and Management of Depression in Adults (Updated Edition). 2010
   Google Scholar
• Wessling A, Ramsberg J. The Review of Antidepressants. 2008
   Google Scholar
• Al-Harbi KS. Treatment-resistant depression: therapeutic trends, challenges, and future directions. Patient Prefer Adherence 2012;6:369-88
   PubMed Web of Science ®Google Scholar
• Anderson IM, Ferrier IN, Baldwin RC, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol 2008;22:343-96
   PubMed Web of Science ®Google Scholar
• Suehs B, Argo T, Bendele S, et al. Edication Algorithm Project Procedural Manual: Major Depressive Disorder Algorithms. JPS Health Network. 2008. https://www.jpshealthnet.org/sites/default/files/tmap_depression_2010.pdf
   Google Scholar
• Khandker RK, Kruzikas DT, McLaughlin TP. Pharmacy and medical costs associated with switching between venlafaxine and SSRI antidepressant therapy for the treatment of major depressive disorder. J Manag Care Pharm 2008;14:426-41
   PubMed Web of Science ®Google Scholar
• Rush AJ, Trivedi MH, Wisniewski SR, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 2006;354:1231-42
   PubMed Web of Science ®Google Scholar
• Bang-Andersen B, Ruhland T, Jorgensen M, et al. Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem 2011;54:3206-21
   PubMed Web of Science ®Google Scholar
• Mork A, Pehrson A, Brennum LT, et al. Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder. J Pharmacol Exp Ther 2012;340:666-75
   PubMed Web of Science ®Google Scholar
• Areberg J, Luntang-Jensen M, Sogaard B, Nilausen DO. Occupancy of the serotonin transporter after administration of Lu AA21004 and its relation to plasma concentration in healthy subjects. Basic Clin Pharmacol Toxicol 2012;110:401-4
   PubMed Web of Science ®Google Scholar
• EMA. Summary of Opinion (Initial Authorisation): Brintellix. http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002717/WC500153088.pdf 2013
   Google Scholar
• FDA. FDA News Release: FDA Approves New Drug to Treat Major Depressive Disorder Food and Drug Administration. 2013. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm370416.htm.
   Google Scholar
• Alvarez E, Perez V, Dragheim M, et al. A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder. Int J Neuropsychopharmacol 2012;15:589-600
   PubMed Web of Science ®Google Scholar
• Boulenger JP, Loft H, Olsen CK. Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder. Int Clin Psychopharmacol 2014;29:138-49
   PubMed Web of Science ®Google Scholar
• Mahableshwarkar AR, Jacobsen PL, Chen Y, et al. A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD. Psychopharmacology (Berl) 2015 Jun; 232(12):2061-70
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Nielsen RZ, Poulsen LH, Haggstrom L. A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine. Hum Psychopharmacol 2014;29:470-82
   PubMed Web of Science ®Google Scholar
• Bondolfi G. A stepwise drug treatment algorithm to obtain complete remission in depression: a Geneva study. Swiss Med Wkly 2006;136:78-85
   PubMed Web of Science ®Google Scholar
• Kasper S. Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. Int J Neuropsychopharmacol 2007;10:661-73
   PubMed Web of Science ®Google Scholar
• Kasper S, Hajak G. The efficacy of agomelatine in previously-treated depressed patients. Eur Neuropsychopharmacol 2013;23:814-21
   PubMed Web of Science ®Google Scholar
• NICE. Single Technology Appraisal (STA): Specification for Manufacturer/Sponsor Submission of Evidence. National Institute for Health and Care Excellence. 2012. https://www.nice.org.uk/proxy/?sourceurl=http://www.nice.org.uk/aboutnice/howwework/devnicetech/specificationformanufacturersponsorsubmissionofevidence.jsp
   Google Scholar
• G-BA. The benefit assessment of pharmaceuticals in accordance with the German Social Code, Book Five (SGB V), section 35a. Available at: http://www.g-ba.de/institution/themenschwerpunkte/arzneimittel/nutzenbewertung35a/anlagen/#abschnitt-3 [Last accessed October 2013]
   Google Scholar
• HAS. Analysis of the literature and recommendations grading guide. Available at: http://www.has-sante.fr/portail/jcms/c_266796/fr/analyse-litterature-medicale-guide-methodologique-2000pdf [Last accessed October 2013]
   Google Scholar
• Zimmerman M, Posternak MA, Chelminski I. Derivation of a definition of remission on the Montgomery–Asberg depression rating scale corresponding to the definition of remission on the Hamilton rating scale for depression. J Psychiatr Res 2004;38:577-82
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Green SE. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011
   Google Scholar
• GSK. Clinical Evaluation of Bupropion Sustained Release (SR) in Patients with Depression – Placebo-Controlled, Double-Blind, Comparative Study in Patients with Depression Who Did Not Respond Sufficiently to Selective Serotonin Re-uptake Inhibitors – AK1102365. Clinicaltrial.gov, 2009
   Google Scholar
• Haggstrom L, Nielsen RZ, Danchenko N et al. A randomised, double-blind, study of vortioxetine versus agomelatine in adults with major depressive disorder (MDD) with inadequate response to SSRI/SNRI treatment. Eur Neuropsychopharmacol 2013;23:S412
   Google Scholar
• Kasper S, Hajak G, Wulff K et al. Efficacy of the novel antidepressant agomelatine on the circadian rest-activity and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline. J Clin Psychiatry 2010;7:109-20
   Google Scholar
• Boren JJ. The effectiveness of antidepressant medications: results from a major new study. Behavior Therapist 2007;30:96-9
   Google Scholar
• Fava M, Rush AJ, Alpert JE et al. Difference in treatment outcome in outpatients with anxious versus non anxious depression: A STAR*D report. Am J Psychiatry 2008;165:342-51
   PubMed Web of Science ®Google Scholar
• Gaynes BN, Farley JF, Dusetzina SB et al. Does the presence of accompanying symptom clusters differentiate the comparative effectiveness of second-line medication strategies for treating depression? Depression Anxiety 2011;28:989-98
   PubMed Web of Science ®Google Scholar
• Gaynes BN, Warden D, Trivedi MH et al. What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression. Psychiatric Services 2009;60:1439-45
   PubMed Web of Science ®Google Scholar
• Haley CL ,Sung SC, Rush AJ et al. The clinical relevance of self-reported premenstrual worsening of depressive symptoms in the management of depressed outpatients: A STAR*D report. J Wom Health 2013;22:219-29
   PubMed Web of Science ®Google Scholar
• Katz AJ , Dusetzina SB, Farley JF et al. Distressing adverse events after antidepressant switch in the sequenced treatment alternatives to relieve depression (STAR*D) trial: influence of adverse events during initial treatment with citalopram on development of subsequent adverse events with an. alternative antidepressant. Pharmacotherapy 2012;32:234-43
   PubMed Web of Science ®Google Scholar
• Kennedy GJ. The sequenced treatment alternatives to relieve depression studies: how applicable are the results for older adults? Primary Psychiatry 2006;13:33-6
   Google Scholar
• Perlis RH , Uher R, Perroud N et al. Do suicidal thoughts or behaviors recur during a second antidepressant treatment trial? J Clin Psychiatry 2012;73:1439-42
   PubMed Web of Science ®Google Scholar
• Rush AJ , Wisnieswski SR , Warden D et al Selecting among second-step antidepressant medication monotherapies: predictive value of clinical, demographic, or first-step treatment features. Arch Gen Psychiatry 2008;65:870-81
   PubMed Web of Science ®Google Scholar
• Rush AJ , Warden D, Wisniewski SR et al. STAR*D: revising conventional wisdom. CNS Drugs 2009;23:627-47
   PubMed Web of Science ®Google Scholar
• Thase ME , Friedman ES, Biggs MM et al Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: A STAR*D report. Am J Psychiatry 2007;164:739-52
   PubMed Web of Science ®Google Scholar
• Trivedi MH , Rush AJ, Gaynes BN et al. Maximizing the adequacy of medication treatment in controlled trials and clinical practice: STAR*D measurement-based care. Neuropsychopharmacology 2007;32:2479-89
   PubMed Web of Science ®Google Scholar
• Trivedi MH , Morris DW, Wisniewski SR et al. Increase in work productivity of depressed individuals with improvement in depressive symptom severity. Am J Psychiatry 2013;170:633-41
   PubMed Web of Science ®Google Scholar
• Warden D , Rush AJ, Wisniewski SR et al. What predicts attrition in second step medication treatments for depression? A STAR D Report. Int J Neuropsychopharmacol 2009;12:459-73
   PubMed Web of Science ®Google Scholar
• Ziffra MS, Gilmer WS. Star*D: lessons learned for primary care. Primary Psychiatry 2007;14:51-8
   Google Scholar
• Lenox-Smith AJ, Jiang Q. Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor. Int Clin Psychopharmacol 2008;23:113-19
   PubMed Web of Science ®Google Scholar
• Rosso G , Rigardetto S, Bogetto F et al. A randomized, single-blind, comparison of duloxetine with bupropion in the treatment of SSRI-resistant major depression. J Affect Disord 2012;136:172-6
   PubMed Web of Science ®Google Scholar
• Birkenhager TK, van den Broek WW, Mulder PG et al. Efficacy and tolerability of tranylcypromine versus phenelzine: a double-blind study in antidepressant-refractory depressed inpatients. J Clin Psychiatry 2004;65:1505-10
   PubMed Web of Science ®Google Scholar
• Perahia DG, Quail D, Desaiah D et al. Switching to duloxetine in selective serotonin reuptake inhibitor non- and partial-responders: effects on painful physical symptoms of depression. J Psychiatric Res 2009;43:512-18
   PubMed Web of Science ®Google Scholar
• Perahia DGS, Quail D, Desaiah D et al. Switching to duloxetine from selective serotonin reuptake inhibitor antidepressants: a multicenter trial comparing 2 switching techniques. J Clin Psychiatry 2008;69:95-105
   PubMed Web of Science ®Google Scholar
• Thase ME, Shelton RC, Khan A. Treatment with venlafaxine extended release after SSRI nonresponse or intolerance: a randomized comparison of standard- and higher-dosing strategies. J Clin Psychopharmacol 2006;26:250-8
   PubMed Web of Science ®Google Scholar
• Bose A , Tsai J, Li D. Early non-response in patients with severe depression: Escitalopram up-titration versus switch to duloxetine. Clin Drug Investig 2012;32:373-85
   PubMed Web of Science ®Google Scholar
• Nakajima S, Uchida H, Suzuki T et al. Is switching antidepressants following early nonresponse more beneficial in acute-phase treatment of depression? A randomized open-label trial. Progr Neuro Psychopharmacol Biol Psychiatry 2011;35:1983-9
   PubMed Web of Science ®Google Scholar
• Nakajima S, Uchida HU, Suzuki TS et al. Benefits of switching antidepressants following early non response. Eur Neuropsychopharmacol 2009;19:S407
   Google Scholar
• Romera I Pérez V, Menchón JM et al. Early switch strategy in patients with major depressive disorder: a double-blind, randomized study. J Clin Psychopharmacol 2012;32:479-86
   PubMed Web of Science ®Google Scholar
• Menchon J. Early intervention in major depressive disorder. Eur Neuropsychopharmacol 2011;21:S624
   Google Scholar
• Romera I , Pérez V, Menchón JM et al. Early vs. conventional switching of antidepressants in patients with MDD and moderate to severe pain: a double-blind randomized study. J Affect Disord 2012;143:47-55
   PubMed Web of Science ®Google Scholar
• Romera I ,Gilaberte I, Perez V et al. Early antidepressant switch in MDD with pain symptoms: functional improvement. Int J Psychiatry Clin Pract 2011;15:36
   Web of Science ®Google Scholar
• Corya SA , Williamson D, Sanger TM et al. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression. Depression Anxiety 2006;23:364-72
   PubMed Web of Science ®Google Scholar
• Ferreri M , Lavergne F, Berlin I et al. Benefits from mianserin augmentation of fluoxetine in patients with major depression non-responders to fluoxetine alone. Acta Psychiatr Scand 2001;103:66-72
   PubMed Web of Science ®Google Scholar
• Souery D ,Serretti A, Calati R et al. Citalopram versus desipramine in treatment resistant depression: effect of continuation or switching strategies. A randomized open study. World J Biol Psychiatry 2011;12:364-75
   PubMed Web of Science ®Google Scholar
• Benkert O , Szegedi A, Wetzel H et al. Dose escalation vs. continued doses of paroxetine and maprotiline: a prospective study in depressed out-patients with inadequate treatment response. Acta Psychiatr Scand 1997;95:288-96
   PubMed Web of Science ®Google Scholar
• Brecht S, Desaiah D, Marechal ES et al. Efficacy and safety of duloxetine 60 mg and 120 mg daily in patients hospitalized for severe depression: a double-blind randomized trial. J Clin Psychiatry 2011;72:1086-94
   PubMed Web of Science ®Google Scholar
• Costa e Silva J. Randomized, double-blind comparison of venlafaxine and fluoxetine in outpatients with major depression. J Clin Psychiatry 1998;59:352-7
   PubMed Web of Science ®Google Scholar
• Dornseif BE , Dunlop SR, Potvin JH et al. Effect of dose escalation after low-dose fluoxetine therapy. Psychopharmacol Bull 1989;25:71-9
   PubMedGoogle Scholar
• Kornstein SG , Dunner DL, Meyers AL et al. A randomized, double-blind study of increasing or maintaining duloxetine dose in patients without remission of major depressive disorder after initial duloxetine therapy. J Clin Psychiatry 2008;69:1383-92
   PubMed Web of Science ®Google Scholar
• Licht RW, Skovagervej A, Qvitzav S. Mianserin augmentation, sertraline dose increase, or extended duration of treatment in patients with major depression nonresponding after six weeks of sertraline treatment: a randomized, double-blind study. 154th Annual Meeting of the American Psychiatric Association, 5–10 May 2001, New Orleans, LA, USA. NR369
   Google Scholar
• Ruhe HG , Booij J, v Weert HC et al. Evidence why paroxetine dose escalation is not effective in major depressive disorder: a randomized controlled trial with assessment of serotonin transporter occupancy. Neuropsychopharmacology 2009;34:999-1010
   PubMed Web of Science ®Google Scholar
• Mocking RJT , Ruhé HG, Westerink AM et al. Longitudinal interplay between paroxetine and fatty acid metabolism in recovery from major depressive disorder. Eur Neuropsychopharmacol 2014;24:S56-7
   Google Scholar
• Ruhe HG , Booij J, Veltman DJ. Successful pharmacologic treatment of major depressive disorder attenuates amygdala activation to negative facial expressions: a functional magnetic resonance imaging study. J Clin Psychiatry 2012;73:451-9
   PubMed Web of Science ®Google Scholar
• Schweizer ER , Rickels K, Amsterdam JD et al. What constitutes an adequate antidepressant trial for fluoxetine? J Clin Psychiatry 1990;51:8-11
   PubMed Web of Science ®Google Scholar
• Schweizer ER , Rynn M, Mandos LA et al. The antidepressant effect of sertraline is not enhanced by dose titration: results from an outpatient clinical trial. Int Clin Psychopharmacol 2001;16:137-43
   PubMed Web of Science ®Google Scholar
• Suri RA , Altshuler LL, Rasgon NL et al. Efficacy and response time to sertraline versus fluoxetine in the treatment of unipolar major depressive disorder. J Clin Psychiatry 2000;61:942-6
   PubMed Web of Science ®Google Scholar
• Licht RW , Qvitzau S. Treatment strategies in patients with major depression not responding to first-line sertraline treatment: a randomised study of extended duration of treatment, dose increase or mianserin augmentation. Psychopharmacology 2002;161:143-51
   PubMed Web of Science ®Google Scholar
• Heo M, Murphy CF, Meyers BS. Relationship between the Hamilton Depression Rating Scale and the Montgomery–Asberg Depression Rating Scale in depressed elderly: a meta-analysis. Am J Geriatr Psychiatry 2007;15:899-905
   PubMed Web of Science ®Google Scholar
• Carmody TJ, Rush AJ, Bernstein I, et al. The Montgomery Asberg and the Hamilton ratings of depression: a comparison of measures. Eur Neuropsychopharmacol 2006;16:601-11
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association: work group on major depressive disorder. Practice Guidelines for the Treatment of Patients with MDD, 3rd edn. American Psychiatric Association. 2010. https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf
   Google Scholar
• Gaynes BN, Dusetzina SB, Ellis AR, et al. Treating depression after initial treatment failure: directly comparing switch and augmenting strategies in STAR*D. J Clin Psychopharmacol 2012;32:114-19
   PubMed Web of Science ®Google Scholar
• Plesnicar BK. Efficacy and tolerability of agomelatine in the treatment of depression. Patient Prefer Adherence 2014;8:603-12
   PubMed Web of Science ®Google Scholar
• Cipriani A, La FT, Furukawa TA, et al. Sertraline versus other antidepressive agents for depression. Cochrane Database Syst Rev 2010;4:CD006117
   Google Scholar
• Maneeton N, Maneeton B, Eurviriyanukul K, Srisurapanont M. Efficacy, tolerability, and acceptability of bupropion for major depressive disorder: a meta-analysis of randomized-controlled trials comparison with venlafaxine. Drug Des Devel Ther 2013;7:1053-62
   PubMed Web of Science ®Google Scholar
• de Silva VA, Hanwella R. Efficacy and tolerability of venlafaxine versus specific serotonin reuptake inhibitors in treatment of major depressive disorder: a meta-analysis of published studies. Int Clin Psychopharmacol 2012;27:8-16
   PubMed Web of Science ®Google Scholar
• Komossa K, Depping AM, Gaudchau A, et al. Second-generation antipsychotics for major depressive disorder and dysthymia. Cochrane Database Syst Rev 2010;12:CD008121
   PubMed Web of Science ®Google Scholar
• Dental and Pharmaceutical Benefits Agency. The Review of Antidepressants. TLV 2008 http://www.tlv.se/upload/genomgangen/review-antidepressants.pdf
   Google Scholar
• Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997;50:683-91
   PubMed Web of Science ®Google Scholar
• Glenny AM, Altman DG, Song F, et al. Indirect comparisons of competing interventions. Health Technol Assess 2005; 9(26):1-134, iii-iv
   Web of Science ®Google Scholar